Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02327169
Title A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib or Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications
Therapies
Age Groups: adult
Covered Countries USA | GBR | FRA | ESP

Facility Status City State Zip Country Details
Massachusetts General Hospital Cancer Center Boston Massachusetts 2114 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 2115 United States Details
Dana Farber Cancer Institute Boston Massachusetts 2115 United States Details
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 United States Details
The University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
Institut Bergonie Bordeaux cedex Gironde 33076 France Details
Institut Claudius Regaud-Oncopole Toulouse cedex 09 Haute Garonne 31059 France Details
Institut Gustave Roussy Villejuif cedex Val De Marne 94805 France Details
Hospital Universitari Vall d'Hebron Barcelona 8035 Spain Details
START Madrid. Fundacion Jimenez Diaz Madrid 28040 Spain Details
Hospital Clinico Universitario Virgen de la Victoria Malaga 29010 Spain Details
Sarah Cannon Research Institure UK London Greater London W1G 6AD United Kingdom Details
The Chrisie Manchester Greater Manchester M20 4BX United Kingdom Details
Churchill Hospital Oxford Oxfordshire OX3 7LJ United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field